SAN CARLOS, Calif., August 5, 2026. BeOne Medicines reported second-quarter revenue of approximately $1.7 billion, up about 30% from the prior-year period, and raised its full-year outlook as Brukinsa continued to anchor the company’s commercial expansion.

Revenue from Brukinsa, the company’s BTK inhibitor, reached roughly $1.2 billion, representing growth of about 31%. The performance reinforces the product’s role as the financial engine supporting BeOne’s broader oncology portfolio and internally developed pipeline.

The company now expects 2026 revenue of $6.6 billion to $6.8 billion. It also projected GAAP operating income of approximately $1 billion to $1.1 billion, signalling a stronger operating profile than is typical for companies still investing heavily across a large clinical portfolio.

Brukinsa competes in a crowded blood-cancer market where prescribers weigh efficacy, tolerability, label breadth and long-term clinical experience. Continued growth suggests that BeOne is translating clinical differentiation into broader adoption across regions and indications.

Beyond Brukinsa, investors are watching how the company converts a pipeline of haematology and solid-tumour candidates into additional commercial products. Recent progress includes the May accelerated approval of Beqalzi, adding another asset to the company’s oncology franchise. The next test will be whether new launches and late-stage programmes can reduce dependence on a single dominant brand.

The quarter also illustrates a wider shift in global biopharma. Companies with research networks, clinical operations and commercial reach across the United States, Europe and Asia are increasingly positioned to develop assets across multiple markets from the outset. That model can accelerate enrolment and broaden revenue opportunities, although it also increases regulatory and execution complexity.

For the sector, BeOne’s raised guidance offers a useful marker of what successful scale can look like after years of pipeline investment. Commercial growth is now being paired with expected operating profit, giving the company more capacity to fund internal research without relying as heavily on external capital.

The durability of that model will depend on Brukinsa’s competitive position, the quality of follow-on launches and disciplined spending across a wide portfolio. For now, the second-quarter update shows that BeOne is entering the second half of 2026 with greater revenue momentum and a higher financial baseline.